The addition of glucagon agonism is believed to further enhance energy expenditure and lipolysis (fat breakdown)
Clinical Evidence Summary Study Type: Retrospective analysis (not a randomized controlled trial) Participants: 1,131 program completers with BMI 30 Duration: 52-68 weeks Primary Outcome: 19.5% average body weight reduction at 52 weeks Medication: 95.4% compounded semaglutide, 4.6% branded semaglutide Control Group: None Funding/Authors: Ivm Health-affiliated authors (conflict of interest disclosed) Publication: Obesity Pillars , 2025 (PubMed indexed, peer-reviewed) Key Limitation: Self-selected completers
Within the first one to two weeks of the protocol, patients commonly report deeper, more restorative sleep with clearer energy on waking
This change, implemented in 2023, aligns Ozempics label with those of related GLP-1 drugs like Wegovy and Mounjaro, which had previously listed this risk
Mounjaro works by helping the body release insulin when blood sugar is high, remove excess sugar from the blood, stop the liver from making and releasing too much sugar, reduce how much food is eaten and slow down how quickly food leaves the stomach
